Compare TATT & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TATT | DNA |
|---|---|---|
| Founded | 1985 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 637.0M | 607.1M |
| IPO Year | 2002 | N/A |
| Metric | TATT | DNA |
|---|---|---|
| Price | $54.72 | $6.77 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | ★ $53.60 | $8.50 |
| AVG Volume (30 Days) | 98.0K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.38 | $1.60 |
| Revenue Next Year | $17.53 | N/A |
| P/E Ratio | $38.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.92 | $5.00 |
| 52 Week High | $64.50 | $17.58 |
| Indicator | TATT | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 49.46 | 40.48 |
| Support Level | $36.84 | $6.54 |
| Resistance Level | $64.50 | $10.05 |
| Average True Range (ATR) | 3.40 | 0.56 |
| MACD | -0.27 | -0.09 |
| Stochastic Oscillator | 21.37 | 15.26 |
TAT Technologies Ltd provides solutions and services to the commercial and military aerospace and ground defense industries, focused mainly on three product areas and services: Thermal Management, Power and Actuation, and Maintenance, Repair and Overhaul (MRO). Its product portfolio includes heat exchangers, cooling systems, and mechanical aircraft accessories and systems such as pumps, valves, and turbine power units. Its operating segments are MRO services for aviation components, which derive key revenue, Original equipment manufacturing (OEM) of heat transfer solutions and aviation accessories, MRO services for heat transfer components and OEM of heat transfer solutions, and Overhaul and coating of jet engine components. Geographically, it derives key revenue from the United States.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.